Glaucoma is a leading cause of irreversible blindness worldwide. Elevated intraocular
pressure (IOP) is considered to be a predominant risk factor for primary open angle …

The ocular drug discovery field has evidenced significant advancement in the past decade.
The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet …

Herein, we described a nickel-catalyzed monofluoroalkenylation through defluorinative
reductive cross-coupling of gem-difluoroalkenes with alkyl halides. Key to the success of this …

A total of 29 novel quinazoline-2-aminothiazole hybrids containing a 4-piperidinylamide
linker were designed, synthesized, and evaluated for their anti-microbial properties against …

LIM kinases are common downstream effectors of several signalization pathways and
function as a signaling node that controls cytoskeleton dynamics through the …

This review provides a comprehensive update on emerging ROCK inhibitors as an
innovative treatment option for lowering intraocular pressure (IOP) in glaucoma and aims to …

Glaucoma a debilitating disease, is globally the second most common kind of permanent
blindness. Primary open-angle glaucoma (POAG) is its most prevalent form and is often …

Butyrylcholinesterase (BChE) is a nonspecific cholinesterase enzyme that hydrolyzes
choline-based esters. BChE plays a critical role in maintaining normal cholinergic function …

Glaucoma, the most common cause of irreversible blindness worldwide, usually causes
characteristic optic nerve damage. Pathological intraocular pressure (IOP) elevation is a …

Triple-negative breast cancer (TNBC) is a highly metastatic breast cancer subtype and due
to the lack of hormone receptors and HER2 expression, TNBC has limited therapeutic …